Wanbury's Patalganga Unit Achieves GMP Accreditation by ANVISA, Enhancing Worldwide Growth Opportunities

Wanbury Limited has issued a statement declaring that its Patalganga manufacturing unit in Maharashtra has achieved the coveted Good Manufacturing Practices (GMP) certificate from ANVISA, the Brazilian Health Regulatory Agency. The accreditation came after a stringent audit, which is a major achievement for the business's worldwide ambitions.

 

The ANVISA inspection, which was carried out in December 2024, ended with zero observations, highlighting Wanbury's uncompromising commitment to global quality and safety standards. This follows a similar feat at Wanbury's facility at Tanuku in Andhra Pradesh, which also passed the ANVISA and US FDA inspections with zero observations earlier this year.

 

ANVISA's GMP certification is important for Wanbury's export to Brazil and other Latin America regulated markets, acknowledging the company's quality and compliance commitment. The Patalganga facility, having already received US FDA approval, is a central location for making Metformin HCl and other APIs, facilitating exports to more than 70 nations globally.

 

With this double achievement, Wanbury is well placed to drive business expansion, increase its international presence, and consolidate its position as a preeminent producer of quality pharmaceutical intermediates.

 

Sources: Economic Times Health, BSE Corporate Filings, Indian Pharma Post, Wanbury Limited